Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

On July 16, 2025, Bio-Thera Solutions, Ltd. (“Bio-Thera”) announced that the U.S. Food and Drug Administration (“FDA”) had accepted its ...

Age at diagnosis, when treated as a continuous variable, appears to impact long-term remission outcomes among patients with JIA.

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

What’s behind the rise in maternal mental health struggles? And more importantly, what can be done to help mothers dealing ...

When former Spice Girl Mel B revealed that she was temporarily blinded in one eye due to a herpes-related complication, it ...

The Department for Work and Pensions (DWP) has fleshed out eligibily for a key benefit worth £110 per week - and dozens of ...

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug ...

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.